• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938

Introduction to 7-Bromoquinoline-2-carboxylic acid (CAS No. 1057217-63-6)

7-Bromoquinoline-2-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1057217-63-6, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinoline family, a class of molecules known for their broad spectrum of biological activities and utility in drug development. The presence of a bromine substituent at the 7-position and a carboxylic acid group at the 2-position imparts unique chemical and pharmacological properties, making it a valuable scaffold for synthesizing novel therapeutic agents.

The quinoline core structure is renowned for its role in antimicrobial, antimalarial, and anticancer applications. Modifications to this core, such as the introduction of halogen atoms or carboxylic acid functionalities, can significantly alter its biological profile. Specifically, 7-Bromoquinoline-2-carboxylic acid has been explored for its potential in inhibiting various enzymes and receptors involved in pathogenic processes. Its structural features make it a versatile intermediate in organic synthesis, facilitating the development of derivatives with enhanced pharmacological efficacy.

Recent advancements in computational chemistry and high-throughput screening have highlighted the importance of 7-Bromoquinoline-2-carboxylic acid in drug discovery. Studies have demonstrated its ability to interact with target proteins through both hydrophobic and electrostatic interactions, which are critical for drug binding affinity. The bromine atom at the 7-position serves as a handle for further functionalization via cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, enabling the construction of more complex molecular architectures.

In the realm of medicinal chemistry, 7-Bromoquinoline-2-carboxylic acid has been investigated for its potential role in addressing resistant strains of pathogens. For instance, modifications to the quinoline scaffold have led to the discovery of compounds with improved activity against multidrug-resistant bacteria. The carboxylic acid group at the 2-position provides a site for amide or ester bond formation, allowing for the creation of prodrugs or conjugates that enhance bioavailability and target specificity.

The synthesis of 7-Bromoquinoline-2-carboxylic acid typically involves multi-step organic transformations starting from commercially available precursors. Common synthetic routes include bromination of quinoline derivatives followed by carboxylation at the 2-position. Advances in green chemistry have also led to the development of more sustainable methods, such as catalytic bromination and carbon dioxide-mediated carboxylation, which minimize waste and improve atom economy.

From a pharmacological perspective, 7-Bromoquinoline-2-carboxylic acid has shown promise in preclinical studies as a modulator of inflammatory pathways. Quinoline derivatives are known to interact with enzymes like cyclooxygenase (COX) and lipoxygenase (LOX), which are central to inflammation. By inhibiting these enzymes, 7-Bromoquinoline-2-carboxylic acid and its derivatives may offer therapeutic benefits in conditions such as arthritis or inflammatory bowel disease.

The compound's solubility profile is another critical factor influencing its pharmaceutical applicability. While quinolines are often hydrophobic, introducing polar functional groups like carboxylic acids can enhance water solubility. This property is particularly important for oral formulations or injectable drugs, where bioavailability is a key consideration. Researchers have explored various salt forms and solubilization techniques to optimize the pharmacokinetic properties of 7-Bromoquinoline-2-carboxylic acid derivatives.

Emerging research also highlights the role of 7-Bromoquinoline-2-carboxylic acid in anticancer therapy. Quinoline-based compounds have been shown to induce apoptosis in cancer cells by disrupting microtubule formation or inhibiting tyrosine kinases. The bromine substituent enhances binding affinity to these targets, making it an attractive moiety for oncology drug design. Preclinical studies have demonstrated that certain derivatives exhibit potent cytotoxicity against various cancer cell lines while maintaining low toxicity towards healthy cells.

The development of novel analytical techniques has further facilitated the study of 7-Bromoquinoline-2-carboxylic acid and its derivatives. High-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are routinely employed to characterize structural purity and quantify bioactive compounds in pharmaceutical formulations. These tools have enabled researchers to optimize synthetic pathways and ensure compliance with regulatory standards.

In conclusion, 7-Bromoquinoline-2-carboxylic acid (CAS No. 1057217-63-6) represents a compelling example of how structural modifications can enhance biological activity. Its unique combination of functional groups makes it a valuable building block for drug discovery efforts targeting infections, inflammation, and cancer. As research continues to uncover new therapeutic applications, this compound is poised to play an increasingly important role in modern medicine.

• 65148-10-9(6-Bromoquinoline-2-carboxylic acid)
• 16732-64-2(4-Bromo-1H-indole-2-carboxylic Acid)
• 16732-65-3(6-bromo-1H-indole-2-carboxylic acid)
• 1017412-53-1(5-Bromoquinoline-2-carboxylic acid)
• 7254-19-5(5-Bromo-1H-indole-2-carboxylic acid)
• 660830-63-7(7-Bromoisoquinoline-3-carboxylic acid)
• 1111311-65-9(5-Bromoisoquinoline-1-carboxylic acid)
• 209003-46-3(4-Bromoquinoline-2-carboxylic acid)
• 914208-15-4(8-Bromoquinoline-2-carboxylic acid)
• 1355174-78-5(Methyl 5-bromoquinoline-2-carboxylate)